Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cabazitaxel in High-Risk Localized Prostate Cancer
2013-001062-41Phase 2Terminated
- Sponsor
- RWTH Aachen University
- Start
- Apr 2013
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in prostate cancer (PCa), sponsored by RWTH Aachen University. Primary endpoint: Pathologic complete response rate. Started Apr 2013; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2013-001062-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001062-41.